Introduction
Non-medullary forms of thyroid cancer are derived from the epithelial cells of the thyroid and account for~90% of all thyroid cancers (1) . The main subtypes of non-medullary thyroid cancer (NMTC) include papillary and follicular thyroid carcinoma. Less frequent types are anaplastic and Hurthle cell forms of the disease. Unlike medullary thyroid carcinoma, where 20EE25% of cases are familial (2) , inherited factors in NMTC are less well established. A number of epidemiological studies have shown that the risk of NMTC is increased 5EE8-fold in first-degree relatives of NMTC cases (3) . Four familial NMTC loci have been identified through linkage analysis of single families with multiple affected family members. The TCO locus (19p13.2) was identified in a French pedigree with multiple cases of multinodular goiter (MNG) and NMTC (4) . The fPTC locus was mapped to 1q21 in a large, three-generation pedigree in which both papillary thyroid cancer (PTC) and renal papillary carcinoma segregated (5) . MNG1 (14q32) was identified through the study of a single, large Canadian pedigree with 18 MNG cases and two PTC cases (6) . A fourth locus has recently been localized on chromosome 2q21 in a large Tasmanian family (7) . These linkages have been detected in large single families and other families have not shown linkage to these loci (6, 8, 9) , suggesting that the disease is genetically highly heterogeneous. It is therefore very unlikely that sequence changes at these loci will account for most of the familial risk seen in relatives of cases. Whilst part of the residual familial risk could be due to high penetrance mutations in as yet unidentified genes, a polygenic mechanism may provide a more plausible alternative explanation. Alleles conferring relative risks of~2 or less will rarely cause multiplecase families and are difficult or impossible to identify through linkage (10) . The search for low penetrance alleles has therefore centred on association studies based on comparing the frequency of polymorphic genotypes in cases and controls. Alleles positively associated with the disease are analogous to risk factors in epidemiology and may be causally related to disease risk or in linkage disequilibrium with disease-causing variants (11) .
Thyroglobulin (Tg) is the most highly expressed protein in the thyroid gland and functions as a scaffold protein for thyroid hormonogenesis and as storage protein for thyroid hormones and iodide. Tg mRNA levels are low in NMTC (12) , and germline Tg abnormalities have been reported in association with goiter (13EE15). Goiter is frequently observed in NMTC pedigrees and is an established risk factor for NMTC in general (16) .
TSHR (thyroid stimulating hormone receptor) is a G-proteincoupled receptor and binds the thyroid stimulating hormone (TSH), the main stimulator of growth and function of normal follicular cells. Germline mutations in TSHR have been shown to co-segregate with hyperthyroidism and thyroid hyperplasia in six families (17) . Mutated forms of TSHR and adenylate cyclase-activating Gs protein have also been observed in thyroid tumors (18EE21).
Given the role of the Tg and TSHR genes in non-malignant thyroid disease, these represent strong candidate NMTC susceptibility loci.
It is conceivable that subtle variations in Tg or TSHR activity, a consequence of polymorphic variation, may confer an increased risk of NMTC. The sequence change 7589A 3 G in Tg is the basis of the Q2511R polymorphism (22) . Two polymorphisms in TSHR have been associated previously with non-malignant thyroid diseaseÐthe P52T and autoimmune thyroid disease (23) and the D727E with goiter (24) .
To examine the proposition that genetic variation in TG or TSHR, defined by these polymorphisms, is a determinant of NMTC risk we compared the frequency of these in cases and controls from two study populations.
Materials and methods

Subjects
Two study groups were analyzed. Table I details the demographic features of the patients and controls from both the study populations. In both groups cases had histologically proven NMTCÐpapillary, follicular, Hurtle cell, or mixed papillary and follicular cancers. The study was undertaken with local ethical board approval at each center in accordance with the tenets of the Helsinki accord.
Study group 1: Canadian cohort. A total of 249 prevalent cases of NMTC diagnosed at ENT clinics of the Sir Mortimer B DavisEEJewish General Hospital and the Montreal General Hospital, Montreal between 1986 and 1996 were eligible for the study. This represents around one-third of all NMTC cases diagnosed in the Montreal area of Canada during this period. Of these, 71 were not included in the study for the following reasonsÐ26 refused to participate, 43 were untraceable, two were deemed unable to complete a questionnaire and provide informed consent. Of the 178 remaining 153 provided a blood sample. Cases who could not be contacted or did not participate were not significantly different from the rest of the cohort in terms of age, gender or histology.
A series of outpatient controlsÐpatients (with non-thyroid related disease) and spousesÐwere recruited. Exclusion criteria included a history of benign or malignant thyroid disease or malignancy of any type (except non-melanotic skin cancer). Each control was matched to a case for sex, year of birth (AE5 years) and ancestral country of origin (at least two of four grandparents of controls had to have the same ethnic origin as the case). All were resident within the Montreal area.
Twenty-nine samples had incomplete data for at least one of three polymorphic loci after molecular analysis, and one case and nine controls did not have sufficient DNA to complete testing, which lead to the exclusion of 39 matched pairs. Therefore, 102 matched cases and controls were included in the final genotypic analysis of all three markers. London, between the years 1994 and 1996. These hospitals are tertiary referral centers serving the population within South England. The number of cases analyzed in this study represents~50% of all patients under review. There was no selection of cases on the basis of family history, age, sex or histology. Blood samples from 298 healthy spouses of lung cancer cases being recruited as part of a National Cancer Research Network Trial within the UK, between the years 1999 and 2002, served as controlsÐ91 males and 207 females. None of the controls had a personal history of malignancy. All the cases and controls were Caucasian and their ancestry was from the British Isles.
Molecular analyses
Genomic DNA was extracted from peripheral blood using conventional methods. The Q2511R polymorphism in Tg results from a single base-pair change (7589A 3 G), which leads to the creation of a novel Taq1 restriction site. The region flanking codon 2511 was amplified using primers 5
H -AACTCAGA-CAGTCTGGCTTCC
Statistical analyses
The relationship between Tg, and TSHR genotypes and risk of NMTC was assessed by means of the odds ratio (OR) with 95% confidence limits calculated by either conditional (study group 1) or unconditional logistic regression (study group 2, adjusting for sex and age). A test for trend (P trend ) in increasing the risk of NMTC by having more than one putative high-risk allele of Tg was also evaluated. To test for population stratification, the distribution of genotypes in cases and controls was tested for a departure from HardyEEWeinberg equilibrium by means of the x test. Pooled estimates of the OR for both studies were obtained by calculating a weighted-average of the logarithm of ORs (26) . Studies were weighted according to the inverse of the variance of the log of the OR. A P-value of 0.05 was considered statistically significant. These computations were undertaken using the statistical software package STATA-Version 7.0 (Stata Corporation, College Station, TX. http://www.stata.com).
The power of each of the studies to demonstrate an association was estimated using the method published by Fleiss et al. (27) , implemented in the statistical program POWER (Epicenter Software, Version 1.30; http:// icarus2.hsc.usc.edu/epicenter/). The population attributable fraction was estimated by (ÂÀ1)/Â, where Â (1 À p) 2 2p(1 À p)OR 1 p 2 OR 2 , given population allele frequency p and OR 1 and OR 2 are the ORs associated with hetero-and homozygosity, respectively. 
Results
The frequency of the TSHR-52T allele in cases and controls in the two studies was 0.06 and 0.07, respectively; the frequency of the TSHR-727E allele was 0.05 in cases and 0.07 in controls. Because of the very small numbers of variant homozygotes observed for these polymorphisms, in estimating ORs we combined data on heterozygotes and variant homozygotes. There was no significant difference in allele frequency of the TSHR P52T and D727E polymorphisms between cases and controls in either of the two study groups (Table II) . Furthermore, there was no evidence for an association from the pooled analysis. Despite their close physical proximity, there was no evidence from either study that the alleles at the two TSHR loci are in linkage disequilibrium (data not shown). Table II also details the frequencies of Tg genotypes in cases and controls in the two study groups and the pooled analysis of the ORs from the two studies. The distribution of Tg Q2511R genotypes in cases and controls in both study groups were in HardyEEWeinberg equilibrium. The frequency of Tg-2511R allele was higher in cases than controls in both study groups (0.55 versus 0.51, and 0.55 versus 0.47 in study groups 1 and 2, respectively). These differences in allele frequency were reflected in the ORs associated with Q2511R hetero-and homozygosity, although statistical significance was only reached in study group 2. Pooling data from analysis of the two groups the ORs associated with hetero-and homozygosity were 1.6 (95% CI: 1.1EE2.5) and 2.0 (95% CI: 1.2EE3.3), respectively.
Discussion
Previous studies have shown that variants in Tg and TSHR (see OMIM 188450 and 603372 for a review) are associated with an increased risk of a number of benign thyroid disorders. Benign thyroid diseases such as MNG are strong risk factors for NMTC, and mutations in TSHR have been linked directly to tumor formation (20, 21, 28EE30) . Such mutations usually lead to constitutive activation of the receptor signaling activity, which in turn presumably results in uncontrolled growth of the cells. We therefore reasoned that known polymorphisms in these two genes might be associated with an increased risk for NMTC.
Ours is the first allelic association study of NMTC. We did not find any evidence of increased risk of NMTC associated with TSHR variants, P52T and D727E. The first polymorphism we examined, P52T, is located in the extra-cellular domain of the protein. The variant protein is predicted to lack a beta-turn at position 52, which would potentially alter the three-dimensional conformation of the receptor. However, examination of two individuals homozygous for the variant T-allele revealed no abnormality in thyroid function (31) . Another report, which observed an association between the variant D727E and MNG, found that the E variant form of TSHR, when transiently expressed in COS-7 cells, induced a greater cAMP response to TSH stimulation than its wild-type counterpart (24) . However, in vitro expression of both forms of the protein in TSA-201 cells by another group revealed no difference in TSHR activity upon TSH stimulation (32) .
Our study does not, however, preclude the possibility of an association as both study groups had 540% power to demonstrate a relationship if the risk associated with carrier status was~1.5. Furthermore, the combined dataset has only 54% power to detect an association. To evaluate these variants as possible determinants of NMTC susceptibility will require additional sample sets of sufficient size commensurate with the detection of small genotypic risks.
Levels of circulating Tg have been reported to be predictive of NMTC development suggesting the possibility of a causal relationship (33) . The frequency of the R-allele of TgQ2511R was over represented in cases with NMTC in both study groups compared with controls. Only in the UK-based analysis was the allele frequency statistically different between cases and controls. Results from the Canadian study, although showing the same trend, were not statistically significant. Although we cannot entirely exclude the possibility of a type 1 error in the UK study, the power to detect a genotypic risk of 1.5 in the Canadian study is 25%. Hence there is a distinct possibility that the failure to demonstrate an association is a consequence of inadequate power. We have attempted to address this through a meta-analysis of the risk estimates generated in the two studies. Pooling data the risk of NMTC associated with hetero-and homozygosity for the R-allele were 1.6 and 2.0, respectively. The mechanism by which this polymorphism may confer an increased risk of NMTC remains to be established. While the TgQ2511R change might mediate risk through linkage disequilibrium with a functional variant, the glutamine to arginine amino acid substitution is non-conservative and resides within the acetylcholinesterase homologous domain of TG. The putative function of this domain is not yet clear, but as acetylcholinesterase interacts with cell membranes in the nervous system, a similar role for the homologous domain at the C-terminal end of the TG molecule has been proposed for apical membrane interaction (34) . There is direct evidence for functionality of this domain in man with missense mutations being associated with fetal goitre (35) . Furthermore, mutations in this domain in both mouse and rat model systems has been shown to cause storage of apparently misfolded TG molecules in the endoplasmic reticulum leading to congenital goiter and hypothyroidism (36, 37) . Taken together the data suggest that germline variation in Tg might either exert a direct effect on NMTC risk or mediate risk through predisposition to goiter. Although the risk of NMTC associated with the R-allele is modest, the high prevalence of the allele in the general population means that it is likely to make a significant impact on NMTC cancer incidence. On the basis that the allele frequency is~50% in the Caucasian population the risk in hetero-and homozygotes translates to this variant underlying around one-third of all cases. A number of other variants in Tg have been documented. Given our finding it is possible that other variants in the gene may confer an increased risk either independently or by defining a high-risk haplotype. Further studies will be required to confirm this finding and further investigate the precise role of the Tg gene in NMTC pathogenesis.
